Drug-screening and genomic analyses of HER2-positive breast cancer cell lines reveal predictors for treatment response
Sandra Jernström,1,2 Vesa Hongisto,3 Suvi-Katri Leivonen,1,2 Eldri Undlien Due,1 Dagim Shiferaw Tadele,1 Henrik Edgren,4,5 Olli Kallioniemi,4 Merja Perälä,6 Gunhild Mari Mælandsmo,2,7,8 Kristine Kleivi Sahlberg,1,9 1Department of Cancer Genetics, Institute for Ca...
Saved in:
Main Authors: | Jernström S, Hongisto V, Leivonen SK, Due EU, Tadele DS, Edgren H, Kallioniemi O, Perälä M, Mælandsmo GM, Sahlberg KK |
---|---|
Format: | article |
Language: | EN |
Published: |
Dove Medical Press
2017
|
Subjects: | |
Online Access: | https://doaj.org/article/5242fb84bf7e40c0a4884802397f2a64 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
HER-2 positivity is a high risk of recurrence of stage I gastric cancer
by: Seonhoo Kim, et al.
Published: (2021) -
Impact of HER2 receptor status on axillary nodal burden in patients with non-luminal A invasive ductal breast carcinoma
by: Kustic,Domagoj, et al.
Published: (2019) -
Structural, Psychological and Contextual Predictors of Car Use
by: Alin Semenescu, et al.
Published: (2021) -
Aplicaciones médicas de los descubrimientos genómicos
by: Cruz-Coke M,Ricardo
Published: (2001) -
Farmacogenómica de los anticoagulantes orales: la importancia de establecer algoritmos de dosificación en población chilena
by: Guzmán,Neftalí, et al.
Published: (2020)